Redefine RNA-targeting therapeutics
Nucyrna’s oligonucleotide platform can target both Nuclear & Cytoplasmic RNA, enabling unique RNA-targeting capacities for addressing complex pathology.
Our technology has demonstrated a remarkable therapeutic window in CNS and we are focusing on neurodegenerative diseases.
Leadership team
Damon (Feng) Wang, PhD
CEO, co-founder
Joseph Klim, PhD
Director of Neuroscience, co-founder
Scientific founders & advisors
Jonathan Watts, PhD
co-founder & advisor
Robert Brown, MD, DPhil
co-founder & advisor
Evangelos Kiskinis, PhD
co-founder & advisor
Awards and milestones
NuCyRNA started operation in Pagliuca Harvard Life Lab
May 2024
NuCyRNA’s Supporters
